126 results on '"Fernández-Peñas, Pablo"'
Search Results
2. The impact of skin cancer prevention efforts in New South Wales, Australia: Generational trends in melanoma incidence and mortality
3. Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases–an observational study.
4. Drug survival of biologics in psoriasis: An Australian multicentre retrospective study.
5. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
6. Prevalence of skin examination behaviours among Australians over time
7. Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry
8. Proteomics: An emerging approach for the diagnosis and classification of cutaneous squamous cell carcinoma and its precursors
9. Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowen’s Disease, and Cutaneous Squamous Cell Carcinoma
10. Differential proteomic analysis of actinic keratosis, Bowen’s disease and cutaneous squamous cell carcinoma by label-free LC–MS/MS
11. Allergic Contact Dermatitis of the Anogenital Region in Men and Women
12. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma
13. Atypical fibroxanthoma management: Recurrence, metastasis and disease‐specific death
14. Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils
15. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study
16. Informing a position statement on the use of artificial intelligence in dermatology in Australia.
17. Genomic and proteomic findings in early melanoma and opportunities for early diagnosis.
18. Cutaneous toxicities of RAF inhibitors
19. The microbiome and atopic eczema: More than skin deep
20. Behaviour, attitudes and awareness concerning sun exposure in adolescents on the Costa del sol
21. Assessing the value of precision medicine health technologies to detect and manage melanoma.
22. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
23. Localized cutaneous immunoglobulin G4
24. 43927 The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials
25. Image analysis in advanced skin imaging technology
26. Dermatology Over the Rainbow
27. Diffuse melanosis cutis in the setting of BRAFV600E mutant melanoma and treatment with targeted therapies
28. Phototherapy for the treatment of cutaneous graft versus host disease
29. Quality of life in non-melanoma skin cancer
30. Uncovering the unmet needs among psoriasis patients in the Asia‐Pacific region.
31. Cutaneous epithelioid angiosarcoma occurring at a peristomal site
32. Specialised skin cancer spectral library for use in data‐independent mass spectrometry.
33. Atypical Early Follicular Graft-vs-Host Disease
34. Infectious eccrine hidradenitis: sweat glands as the portal of entry for cellulitis.
35. 27043 Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1
36. 25997 Safety of tildrakizumab 100 mg and 200 mg through 5 years of exposure in reSURFACE 1
37. Sun Exposure Habits and Sun Protection Practices of Skaters.
38. Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils.
39. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
40. Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia.
41. 33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2).
42. Systemic and erythrodermic reactions following repeated exposure to bites from the Common bed bug Cimex lectularius (Hemiptera: Cimicidae).
43. Checkmate: The drugs that have cancer on the run: Checkpoint inhibitors offer another approach for tackling advanced melanoma, but there are important adverse events to consider.
44. Localized cutaneous immunoglobulin G4.
45. Diffuse melanosis cutis in the setting of BRAFV600E mutant melanoma and treatment with targeted therapies.
46. Potent topical steroids are one of the treatments for cutaneous T-cell lymphoma
47. Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas.
48. Multiple facial plaques.
49. On target: Taking aim at mutant genes: After many years of standstill and unsuccessful attempts, therapeutic advances have significantly improved the survival of patients with melanoma.
50. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.